Scientists May Have Found How to Predict When Alzheimer's Signs Will Begin
Summary
Researchers at Columbia University found that combining a blood test measuring a protein called p-tau217 with a genetic test for the APOE4 gene can help predict when people at high risk for Alzheimer’s might begin showing symptoms. This method may allow doctors to identify early signs of the disease before major symptoms appear.Key Facts
- The blood test measures p-tau217, a protein linked to Alzheimer’s disease.
- The genetic test looks for the APOE4 gene, which increases Alzheimer’s risk.
- People with both high p-tau217 levels and the APOE4 gene have about a 24% chance of developing Alzheimer’s, compared to 13% without the gene.
- Those with both markers may develop cognitive decline within three to four years.
- The p-tau217 protein rises as Alzheimer’s disease progresses, making it a useful early signal.
- Having APOE4 raises risk but does not guarantee Alzheimer’s will develop.
- The study suggests that the same level of p-tau217 may have different meanings depending on a person’s genetic background.
- The methods may not work equally well across all racial and ethnic groups due to genetic diversity.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
